Cadre and Core Medical's application for an IPO on the Shanghai Stock Exchange has been "accepted".

On November 6th, the Shanghai Stock Exchange announced that Quanzhou Jiadeli Electronic Materials Co., Ltd. (Jiadeli) and Shenzhen Core Medical Technology Co., Ltd. (Core Medical) have had their IPO applications accepted. According to the prospectus, Jiadeli is a national-level specialized and innovative "small giant" enterprise and high-tech enterprise specializing in the research, development, production, and sales of BOPP electrical film. With over 20 years of experience in the BOPP electrical film industry, the company has a rich and highly competitive product matrix. Through long-term technological research and development and process accumulation, the company has continuously made breakthroughs in key technical indicators such as ultra-thin, high temperature resistance, and high voltage resistance. Currently, the company is able to achieve stable production of iconic products such as 1.9m ultra-thin films, 125 high temperature resistant films, 900V ultra-thin films, and 2,000V special pulse films in different product series. These products are widely used in emerging fields such as new energy vehicles, renewable energy, and flexible direct current transmission. The prospectus shows that Core Medical is an Innovative Medical Management equipment company dedicated to providing more comprehensive, innovative, and high-quality artificial heart products. As of the signing date of the prospectus, the company has launched 5 implantable and 6 interventional artificial heart products, with one implantable product already commercialized, two interventional products in the registration approval stage, and multiple artificial heart products in the clinical stage. Among these products, a total of 3 core products have been included in China's Innovative Medical Management equipment special review program, including the implantable left ventricular assist system Corheart 6, the implantable dual ventricular assist system DuoCor 2, and the interventional ventricular assist system CorVad 4.0/6.0 series, making the company the leader in China's artificial heart field in terms of the number of products included.